Migraine preventive therapy: selection of appropriate patients and general principles of management

References

• Lipton RB, Diamond M, Freitag FG, Bigal M, Stewart WF, Reed ML. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) Study, Poster F38. Headache45, 792 (2005).
   Google Scholar
• Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG-2000: medical and therapeutic management of migraine in France. Cephalalgia25(4), 267–280 (2005).
   PubMed Web of Science ®Google Scholar
• Kors EE, Vanmolkot KR, Haan J, Frants RR, van den Maagdenberg AM, Ferrari MD. Recent findings in headache genetics. Curr. Opin. Neurol.17, 283–288 (2004).
   PubMedGoogle Scholar
• Bowyer SM, Aurora SK, Moran JE, Tepley N, Welch KMA. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol.50, 582–587 (2001).
   PubMed Web of Science ®Google Scholar
• Wray SH, Mijovic-Prelec D, Kosslyn SM. Visual processing in migraineurs. Brain118, 25–35 (1995).
   PubMedGoogle Scholar
• Leao AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol.7, 379–390 (1944).
   Google Scholar
• Freitag FG. Divalproex in the treatment of migraine. Psychopharmacol. Bull.37(Suppl. 2), 98–115 (2003).
   PubMedGoogle Scholar
• Welch KMA. Brain hyperexcitabiliy: the basis for antiepileptic drugs in migraine prevention. Headache45(Suppl. 1), S25–S32 (2005).
   Web of Science ®Google Scholar
• Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: insights in migraine pathophysiology using rizatriptan. Neurology55(9 Suppl. 2), S8–S14 (2000).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol.55, 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med.1, 658–660 (1995).
   PubMed Web of Science ®Google Scholar
• Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache41, 941–943 (2001).
   PubMedGoogle Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia23, 519–527 (2003).
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd Edition. Cephalalgia24(Suppl. 1), 1–160 (2004).
   Web of Science ®Google Scholar
• Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C. Migraine and probable migraine: results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia25(12), 1146–1158 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Sheder AL, Simon D, Liberman JN. Migraine prevalence. A review of population-based studies. Neurology44(Suppl. 4), S17–S23 (1994).
   PubMed Web of Science ®Google Scholar
• Abu-Arehf I, Russell G. Prevalence of headache and migraine in schoolchildren. Br. Med. J.309, 765–969 (1994).
   PubMedGoogle Scholar
• Bille B. Migraine in school children: prevalence, clinical features, and a 30-year follow-up. In: Migraine and Other Headaches. Ferrari MD, Lataste X (Eds). Parthenon, NJ, USA (1989).
   Google Scholar
• D’Amico D, Usai S, Grazzi L, Solari A, Curone M, Bussone G. The impact of primary headaches on patients lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care1, 123–128 (2004).
   Google Scholar
• Lambert J, Carides GW, Meloche JP, Gerth WC, Marentette MA. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a Phase III clinical trial. Can. J. Clin. Pharmacol.9(3), 158–164 (2002).
   PubMedGoogle Scholar
• Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilization and work loss. Pharmacoeconomics19, 197–206 (2001).
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med.10, 255–259 (1999).
   Google Scholar
• Dahlöf CHG, Dimenäis E. Migraine patients experience: poor subjective well-being/quality of life even between attacks. Cephalalgia15, 31 (1995).
   PubMed Web of Science ®Google Scholar
• Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology55(Suppl. 2), S29–S36 (2000).
   PubMedGoogle Scholar
• Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology55(5), 629–635 (2003).
   Google Scholar
• Dueland AN, Leira R, Cabelli ST. The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr. Med. Res. Opin.21, 1297–1305 (2005).
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache34, 337–343 (1994).
   PubMed Web of Science ®Google Scholar
• Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology55, 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs – a nation-wide population-based survey in Sweden. Cephalalgia24, 455–465 (2004).
   PubMed Web of Science ®Google Scholar
• Holmes WF, MacGregor EA, Sawyer JP, Lipton RB. Information about migraine disability influences physicians perceptions of illness severity and treatment needs. Headache341, 343–350 (2001).
   Google Scholar
• Stewart WF, Lipton RB, Whyte J et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology53, 988–994 (1999).
   PubMed Web of Science ®Google Scholar
• Kosinski M, Bayliss MS, Bjorner JB et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual. Life Res.12(8), 963–974 (2003).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology58, 885–894 (2002).
   PubMed Web of Science ®Google Scholar
• Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs16(Suppl. 1), 13–18 (2002).
   PubMedGoogle Scholar
• Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology60, 1064–1070 (2003).
   PubMed Web of Science ®Google Scholar
• Gibbs TS, Fleischer AB Jr, Feldman SR, Sam MC, O’Donovan CA. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache43, 330–335 (2003).
   PubMed Web of Science ®Google Scholar
• Vuillaume de Diego E, Lantéri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by headache impact test (HIT). Cephalalgia25, 184–190 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor F, Hutchinson S, Graff-Radford S, Cady R, Harris L. Diagnosis and management of migraine in family practice. J. Fam. Pract. (Suppl.), S3–S24 (2004).
   Google Scholar
• Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology62(Suppl. 2), S2–S8 (2004).
   Google Scholar
• Pryse-Phillips WE, Dodick DW, Edmeads JG et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ156, 1273–1287 (1997).
   PubMed Web of Science ®Google Scholar
• Hu XH, O’Donnell F, Kunkel RS, Gerard G, Markson LE, Burger ML. Survey of migraineurs referred to headache specialist: care, satisfaction, and outcomes. Neurology55, 141–143 (2000).
   PubMedGoogle Scholar
• Geraud G, Lanteri-Minet M, Lucas C, Valade D, French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther.26, 1305–1318 (2004).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D, MIPCA Migraine Guideline Development Group. Migraine in Primary Care Advisors. New guidelines for the management of migraine in primary care. Curr. Med. Res. Opin.18, 414–439 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick D, Sadovsky R et al. A self-administered screener for migraine in primary care. Neurology61, 375–382 (2000).
   Google Scholar
• Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality of life: a population-based case-control study from England. Cephalalgia23, 441–450 (2003).
   PubMed Web of Science ®Google Scholar
• Tepper SJ, D’Amico D, Boas V, Dowson AJ. Guidelines for prescribing prophylactic medications for migraine: a survey among headache specialist physicians in different countries. Headache Care1, 267–272 (2004).
   Google Scholar
• Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology54, 1553 (2000).
   PubMedGoogle Scholar
• Silberstein SD, Lipton RB. Chronic daily headache including transformed migraine, chronic tension-type headache, and medication overuse. In: Wolff’s Headache and Other Head Pain. 7th Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 247–282 (2001).
   Google Scholar
• Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology62(5), 788–790 (2004).
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain106, 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache41, 573–578 (2001).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache43, 336–342 (2003).
   PubMed Web of Science ®Google Scholar
• D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache45(5), 553–560 (2005).
   PubMed Web of Science ®Google Scholar
• Powers C, Szeto S, Pangtay D, Bort T, Cervi M, Cady R. Evaluation of migraineurs preferences for naratriptan over conventional first-line agents. Arch. Fam. Med.9(8), 753–758 (2000).
   PubMedGoogle Scholar
• Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache39(Suppl. 2), S20–S26 (1999).
   Google Scholar
• Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A. START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin. Ther.25(7), 2053–2069 (2003).
   PubMedGoogle Scholar
• MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey – Phase III. Curr. Med. Res. Opin.20, 1143–1150 (2004).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr. Pain Headache Rep.7, 55–62 (2003).
   PubMedGoogle Scholar
• Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache44(Suppl. 1), S20–S30 (2004).
   PubMedGoogle Scholar
• Rahman A, Segasothy M, Samad SA, Zulfiqar A, Rani M. Analgesic use and chronic renal disease in patients with headache. Headache33, 442–445 (1993).
   PubMedGoogle Scholar
• D’Amico D, Solari A, Usai S et al., for the Lombardy Headache Project Group. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. a prospective longitudinal multicenter study. Cephalalgia26(6), 691–696 (2006).
   PubMed Web of Science ®Google Scholar
• Ware JE. SF-36 health survey update. Spine25, 3130–3139 (2000).
   PubMed Web of Science ®Google Scholar
• Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache45(8), 1023–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Migraine preventive medication reduces resource utilization. Headache43, 171–178 (2003).
   PubMed Web of Science ®Google Scholar
• Evans RW, Bigal ME, Grosberg B, Lipton RB. Target doses and titration schedules for migraine preventive medications. Headache46(1), 160–164 (2006).
   PubMedGoogle Scholar
• Palevitch D, Earon G, Carusso R. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother. Res.11, 508–511 (1997).
   Web of Science ®Google Scholar
• Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia16(4), 257–263 (1996).
   PubMed Web of Science ®Google Scholar
• Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology50(2), 466–470 (1998).
   PubMed Web of Science ®Google Scholar
• Allais G, Bussone G, De Lorenzo C, Mana O, Benedetto C. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol. Sci.26(Suppl. 2), S125–S129 (2005).
   Web of Science ®Google Scholar
• Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs19(11), 951–972 (2005).
   PubMed Web of Science ®Google Scholar
• Aube M. Improving patient compliance to prophylactic migraine therapy. Can. J. Neurol. Sci.29(Suppl. 2), S40–S43 (2002).
   Google Scholar
• Ferrari A, Sternieri E, Ferraris E, Bertolini A. Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol. Res.48, 1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Topiramate (Topamax). Physicians’ Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 2541–2548 (2005).
   Google Scholar
• Divalproex (Depakote ER). Physicians’ Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 441–447 (2005).
   Google Scholar
• Propranolol (Inderal LA). Physicians’ Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 3336–3337 (2005).
   Google Scholar
• Verapamil hydrochloride. Physicians’ Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 479–481 (2005).
   Google Scholar
• Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia1, 52–56 (1998).
   Google Scholar
• Massiou H. Migraine medication attributes are important for patient compliance. Drugs Today39(Suppl. D), 25–29 (2003).
   PubMedGoogle Scholar
• Dodick D. Patient perceptions and treatment preferences in migraine management. CNS Drugs16(Suppl. 1), 19–24 (2002).
   PubMedGoogle Scholar
• MacGregor EA. The doctor and the migraine patient: improving compliance. Neurology48(Suppl. 3), S16–S20 (1997).
   Google Scholar
• D’Amico D. Treatment strategies in migraine patients. Neurol. Sci.25, S242–S243 (2004).
   Google Scholar
• Turner A. Development of a complete diary and checklist for headache patients. Headache Care1(3), 199–206 (2004).
   Google Scholar